Cell therapy is advancing in transplantation, but donor-specific antibodies remain a persistent failure point

Cell-based immunotherapy has moved from concept to clinical testing in solid organ transplantation because conventional maintenance immunosuppression still leaves a dangerous gap. Calcineurin inhibitors can suppress T-cell activation, yet they do not directly shut down antibody-producing B cells, and the result is familiar at the bedside: de novo donor-specific antibody continues to emerge after transplant, with downstream antibody-mediated rejection and chronic graft injury. The review places this problem at the center of the field rather than at its margins, arguing that a therapy can look successful on one endpoint while still failing the biologic process that most threatens long-term graft survival. In transplantation, that process is humoral alloimmunity.

The burden is not small. de novo donor-specific antibody occurs in 13% to 35% of kidney transplant recipients, and antibody-mediated rejection develops in 5% to 7% of first-time kidney transplants. Donor-specific antibody is also linked to acute graft failure in sensitized recipients and to late allograft rejection. The same biology extends beyond kidney transplant and appears in heart, lung, pancreas, liver, intestine, islet, and hepatocyte transplantation. Once antibodies are established, simply adjusting tacrolimus exposure or reinforcing adherence rarely reverses the immune trajectory.

Why current antibody-directed strategies have not closed the gap

The clinical logic behind current anti-rejection strategies is straightforward: reduce antibody levels, interrupt complement, or suppress the cells that generate the response. The practical results have been uneven. Corticosteroids, bortezomib, plasmapheresis, intravenous immunoglobulin, complement-directed therapy, and antibody-cleaving approaches have all been used for antibody-mediated rejection, yet their effects are often nonspecific, short-lived, or limited by adverse effects. Even therapies designed to reduce immunoglobulin burden have not consistently changed microvascular inflammation, and HLA-DQ–specific donor-specific antibody remains especially difficult to control.

One sentence captures the problem: existing therapies often blunt the signal without silencing the source.

Imlifidase illustrates the pattern. It showed early promise in pre-transplant desensitization by cleaving IgG and reducing donor-specific antibody more effectively than plasmapheresis, yet it ultimately failed to show clinical benefit in treatment of antibody-mediated rejection. Other immunotherapies aimed at costimulatory pathways, B cells, plasma cells, or cytokines have also run into rebound alloimmunity, acute T cell-mediated rejection, and infection risk. In chronic antibody-mediated rejection, a substantial proportion of recipients receive no therapy beyond maintenance immunosuppression adjustment, which reflects the lack of a reliably effective option rather than therapeutic indifference.

Regulatory T cells remain the most developed transplant cell therapy

Among the cell platforms reviewed, regulatory T cells have the deepest clinical and mechanistic foundation. These cells suppress CD4+ and CD8+ T-cell activity, dampen B-cell responses, influence dendritic cells and macrophages, and can restrain broader inflammatory cascades. Their biology makes them attractive for transplantation because they can shift the immune response toward tolerance rather than simple suppression. In principle, that matters for a field that has long depended on broad immunosuppressive drugs with narrow therapeutic windows.

The review emphasizes a key mechanism: CD25-high regulatory T cells compete for interleukin-2, depriving effector T cells of a growth signal, while TGF-β secretion adds a second layer of suppression. This is a biologically credible way to reduce alloreactivity while preserving some protective immunity. It also explains why Treg therapy is being explored not just as a rejection treatment, but as a strategy to lower the amount of maintenance immunosuppression needed after transplant.

Still, the central question is not whether Tregs can suppress immunity in principle. It is whether they can suppress the antibody arm of alloimmunity long enough to prevent donor-specific antibody from taking hold. The review is cautious on that point, and for good reason: cell therapies may be well tolerated and may help with immunosuppression minimization or withdrawal, yet they have not reliably prevented de novo donor-specific antibody.

Expansion yield, persistence, and trafficking may decide whether these therapies work in practice

The review repeatedly returns to an issue that is easy to overlook in translational work: a therapy can look elegant in vitro and still fail after infusion if the cells do not persist, traffic correctly, or retain function in vivo. Yield after ex vivo expansion, phenotypic stability, compatibility with concomitant immunosuppressive agents, and adverse effects all shape the real-world value of a cellular product. A transplant recipient is not a uniform biologic environment, and infused cells face a host immune system already shaped by prior sensitization, surgery, maintenance drugs, and organ-specific inflammation.

This is why the review calls for better standardization in cell-therapy trials. Current studies have not uniformly reported the same manufacturing and monitoring variables, which makes comparisons difficult and limits the field’s ability to identify the characteristics of a successful product. Baseline in vitro function, purity, persistence after infusion, plasticity, proliferation, and trafficking should all be tracked. So should recipient outcomes that matter most in transplantation: donor-specific antibody, antibody-mediated rejection, T-cell mediated rejection, viral infection, and treatment-related adverse effects.

Mesenchymal stromal cells, hematopoietic stem cells, regulatory dendritic cells, and CXCR5+CD8+ T cells extend the field

Beyond Tregs, the review surveys mesenchymal stem cells, hematopoietic stem cells, regulatory dendritic cells, and experimental CXCR5+CD8+ antibody-suppressor or follicular cytotoxic T-cell populations. Each platform enters transplantation from a different biologic angle. Mesenchymal stem cells are attractive because they can be expanded in vitro and have broad immunomodulatory effects. Hematopoietic stem cells may support tolerance pathways without prolonged culture. Regulatory dendritic cells are designed to shape antigen presentation toward tolerance rather than activation. The CXCR5+CD8+ populations are earlier in development but represent a direct attempt to suppress antibody generation at its follicular source.

These therapies are not interchangeable. Their mechanisms, product yield, and interaction with standard immunosuppression differ in ways that should shape trial design. A therapy that reduces T-cell activation may still leave the B-cell compartment intact. A therapy that dampens inflammation may not prevent long-term antibody maturation. The review’s value lies in forcing those distinctions into the open.

Trial design will need to measure more than rejection rates

Cell therapy in transplantation is often discussed as a path to immune tolerance, but tolerance is not a binary end point. A recipient can have fewer rejection episodes, lower drug exposure, and still develop antibody-mediated injury over time. The review argues for trial designs that capture that complexity. Future studies should not stop at whether a cell product was tolerated or whether maintenance immunosuppression could be reduced. They should measure whether the treatment actually changes humoral alloimmunity.

That requirement makes the field harder, not easier. It also makes it more clinically relevant. If a cellular therapy cannot prevent donor-specific antibody, it may still be useful for reducing drug burden, but it should not be mistaken for a solution to chronic humoral rejection. The review closes that gap by judging transplant cell therapies against the immune process that determines long-term graft survival, not against convenience alone.

DOI and citation

The review appears in Frontiers in Immunology with DOI 10.3389/fimmu.2026.1946651. Its central limitation is also its central contribution: the field still lacks uniform clinical trial reporting, standardized manufacturing metrics, and robust evidence that any current cell therapy can reliably prevent de novo donor-specific antibody after transplantation.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA